ierdenervatie als behandeling van hoge bloeddruk na niertransplantatie.
Suspended
- Conditions
- Therapy resistant hypertensionrenal allograft recipients
- Registration Number
- NL-OMON29017
- Lead Sponsor
- Department of NephrologyAcademic Medical Center at the University of Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Renal graft in situ since > 6 months, estimated GFR >35 ml/min/1,73m2 and;
2. Diuresis of the native kidneys at transplant >200 ml/day (to ensure the presence of vital kidney that could be affected by renal nerve ablation) and;
Exclusion Criteria
1. (Planned) pregnancy, lactation;
2. Life expectancy < 1 year;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change daytime blood pressure after 6 months after renal denervation assessed by ambulatory blood pressure measurement; compared to continued standard care (i.e. comforming to National Kidney Foundation Kidney Disease Quality Outcomes Quality Initiative guidelines).
- Secondary Outcome Measures
Name Time Method 1. Change in 123I-MIBG uptake of native kidneys (i.e. effectiveness of denervation);<br /><br>2. Change in muscle sympathetic nerve activity, plasma catecholamines, rennin and aldosterone;<br /><br>3. Change in proteinuria after 6 months;<br /><br>4. Change in eGFR after 6 months;<br /><br>5. Change in number of antihypertensive drugs;<br /><br>6. Change in health related quality of life.